160 related articles for article (PubMed ID: 36691332)
21. Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway.
Wang Q; Wu H; Wu Q; Zhong S
Drug Dev Res; 2023 Aug; 84(5):907-921. PubMed ID: 37070571
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K/AKT pathway.
Zhu W; Shi L; Gong Y; Zhuo L; Wang S; Chen S; Zhang B; Ke B
Thorac Cancer; 2022 Apr; 13(7):1027-1039. PubMed ID: 35178875
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer.
Xia H; Li Y; Lv X
Int J Oncol; 2016 Oct; 49(4):1325-33. PubMed ID: 27498977
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway.
Han J; Hu J; Sun F; Bian H; Tang B; Fang X
Mol Cell Biochem; 2021 Feb; 476(2):689-698. PubMed ID: 33125611
[TBL] [Abstract][Full Text] [Related]
25. CircRPPH1 promotes cell proliferation, migration and invasion of non-small cell lung cancer via the PI3K/AKT and JAK2/STAT3 signalling axes.
Xiong JW; Song SB; Xiong LM; Duan CH; Song Q; Yu DL; Zhang XQ
J Biochem; 2022 Feb; 171(2):245-252. PubMed ID: 34850004
[TBL] [Abstract][Full Text] [Related]
26. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
[TBL] [Abstract][Full Text] [Related]
27. Circular RNA circ‑ACACA regulates proliferation, migration and glycolysis in non‑small‑cell lung carcinoma via miR‑1183 and PI3K/PKB pathway.
Wu W; Xi W; Li H; Yang M; Yao X
Int J Mol Med; 2020 Jun; 45(6):1814-1824. PubMed ID: 32236577
[TBL] [Abstract][Full Text] [Related]
28. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.
Liu L; Zhou XY; Zhang JQ; Wang GG; He J; Chen YY; Huang C; Li L; Li SQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8722-8730. PubMed ID: 30575912
[TBL] [Abstract][Full Text] [Related]
29. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
30. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
31. RHBDD1 silencing inhibited cell growth and invasion of non-small cell lung cancer by mediating ZEB1/PI3K/AKT signaling pathway.
Xu Z; Wang R; Li X; Yang L; Peng H; Wang Y; Wang P
J Mol Histol; 2021 Jun; 52(3):503-510. PubMed ID: 33515112
[TBL] [Abstract][Full Text] [Related]
32. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
[TBL] [Abstract][Full Text] [Related]
33. Dual roles of miR-374a by modulated c-Jun respectively targets CCND1-inducing PI3K/AKT signal and PTEN-suppressing Wnt/β-catenin signaling in non-small-cell lung cancer.
Zhao M; Xu P; Liu Z; Zhen Y; Chen Y; Liu Y; Fu Q; Deng X; Liang Z; Li Y; Lin X; Fang W
Cell Death Dis; 2018 Jan; 9(2):78. PubMed ID: 29362431
[TBL] [Abstract][Full Text] [Related]
34. Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the PI3K/ Akt/NF-κB Signaling Pathway in Vitro and in Vivo.
Zhou B; Wang D; Sun G; Mei F; Cui Y; Xu H
Cell Physiol Biochem; 2018; 46(3):999-1008. PubMed ID: 29669316
[TBL] [Abstract][Full Text] [Related]
35. microRNA-935 is reduced in non-small cell lung cancer tissue, is linked to poor outcome, and acts on signal transduction mediator E2F7 and the AKT pathway.
Wang C; Li S; Xu J; Niu W; Li S
Br J Biomed Sci; 2019 Jan; 76(1):17-23. PubMed ID: 30203720
[TBL] [Abstract][Full Text] [Related]
36. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
[TBL] [Abstract][Full Text] [Related]
37. WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways.
Meng J; Zhang XT; Liu XL; Fan L; Li C; Sun Y; Liang XH; Wang JB; Mei QB; Zhang F; Zhang T
Cell Signal; 2016 Nov; 28(11):1673-82. PubMed ID: 27449264
[TBL] [Abstract][Full Text] [Related]
38. MiR-4299 suppresses non-small cell lung cancer cell proliferation, migration and invasion through modulating PTEN/AKT/PI3K pathway.
Yang WB; Zhang WP; Shi JL; Wang JW
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3408-3414. PubMed ID: 29917192
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-126 Targeting PIK3R2 Inhibits NSCLC A549 Cell Proliferation, Migration, and Invasion by Regulation of PTEN/PI3K/AKT Pathway.
Song L; Li D; Gu Y; Wen ZM; Jie J; Zhao D; Peng LP
Clin Lung Cancer; 2016 Sep; 17(5):e65-e75. PubMed ID: 27236384
[TBL] [Abstract][Full Text] [Related]
40. Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.
Song P; Song B; Liu J; Wang X; Nan X; Wang J
Clin Transl Oncol; 2021 Apr; 23(4):892-901. PubMed ID: 32974862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
